The priority strategy for SMA newborn screening is to detect category 1 mutations (homozygous SMN1 exon 7 deletion) using cost-effective, high-sensitivity, and high-throughput methods [7, 68]. The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.